129 related articles for article (PubMed ID: 9316167)
1. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Minami H; Nakahara T; Miyahara A; Nakane Y
Psychiatry Clin Neurosci; 1997 Aug; 51(4):217-22. PubMed ID: 9316167
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
3. Total and free plasma neuroleptic levels in schizophrenic patients.
Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
[TBL] [Abstract][Full Text] [Related]
4. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
5. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
6. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
8. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.
Chouinard G
Acta Psychiatr Scand Suppl; 1990; 358():111-9. PubMed ID: 1978469
[TBL] [Abstract][Full Text] [Related]
10. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Ulrich S; Neuhof S; Braun V; Meyer FP
Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
[TBL] [Abstract][Full Text] [Related]
11. Effects of antipsychotic drugs on memory functions of schizophrenic patients.
Eitan N; Levin Y; Ben-Artzi E; Levy A; Neumann M
Acta Psychiatr Scand; 1992 Jan; 85(1):74-6. PubMed ID: 1347670
[TBL] [Abstract][Full Text] [Related]
12. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
Levinson I; Levine S
Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
[No Abstract] [Full Text] [Related]
13. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
14. [Increased blink rate in schizophrenic patients].
Mackert A; Woyth C; Flechtner KM; Frick K
Nervenarzt; 1990 Jul; 61(7):426-30. PubMed ID: 1975431
[No Abstract] [Full Text] [Related]
15. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.
Andreasen NC; Pressler M; Nopoulos P; Miller D; Ho BC
Biol Psychiatry; 2010 Feb; 67(3):255-62. PubMed ID: 19897178
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.
Hong CJ; Chen JY; Chiu HJ; Sim CB
Int Clin Psychopharmacol; 1997 May; 12(3):123-30. PubMed ID: 9248867
[TBL] [Abstract][Full Text] [Related]
17. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
[TBL] [Abstract][Full Text] [Related]
18. Predicting haloperidol treatment response in chronic schizophrenia.
van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
[TBL] [Abstract][Full Text] [Related]
19. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
[TBL] [Abstract][Full Text] [Related]
20. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.
Hogan TP; Awad AG; Eastwood MR
Can J Psychiatry; 1985 Jun; 30(4):246-8. PubMed ID: 2861887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
